Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$250.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

STADA Arzneimittel AG Comments on FY 2013 Sales Growth Guidance; Updates on FY 2014 Sales, EBITDA and Net Income Guidance


Tuesday, 7 May 2013 01:25am EDT 

STADA Arzneimittel AG announced that its Executive Board expects further growth in sales and earnings for the Group in the fiscal year 2013 and 2014. In addition, the Executive Board affirms the long-term prognosis envisaged for fiscal year 2014, according to which Group sales of approximately EUR 2.15 billion, at an adjusted level, EBITDA of approximately EUR 430 million and net income of approximately EUR 215 million should be reached at minimum. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2014 sales of EUR 2,092.53 million, EBITDA of EUR 432.29, and net income of EUR 199.79 million. 

Company Quote

29.13
0.045 +0.15%
11:35am EDT